Azkarra Therapeutics

1 known investors

Azkarra Therapeutics develops small molecule drugs targeting DNA damage repair and immune response pathways for cancer and inflammatory diseases. The company focuses on novel PARP inhibitors, PARG inhibitors, and OGG1 inhibitors as next-generation precision therapeutics.